Filspari (sparsentan)
Research Synopsis
- Filspari (sparsentan) received accelerated FDA approval in February 2023, designed for adults with severe IgA nephropathy, focusing on lowering proteinuria levels.
- Recent studies highlight its effectiveness in managing IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) by acting as a dual receptor antagonist targeting endothelin and angiotensin II receptors.
- The PROTECT trial showed significant reductions in proteinuria for patients with IgAN compared to irbesartan, with promising results over a two-year period.
- Interim analyses and pharmacokinetic studies indicate sparsentan's favorable safety profile and effectiveness, with careful monitoring required for drug interactions, especially involving CYP3A4 inhibitors.
- Dual inhibition appears beneficial, as seen in studies on Alport syndrome, demonstrating sparsentan's potential for addressing both renal and auditory aspects of the disease.
- New reviews emphasize the urgency of personalized treatment strategies due to the complexity of IgAN and the potential roles of sparsentan in advanced management.
- Research also indicates that achieving complete remission of proteinuria is linked to improved kidney function outcomes, further supporting sparsentan's therapeutic value in chronic kidney diseases.
- Ongoing research and trials are critical in exploring broader uses for sparsentan and refining treatment protocols for chronic nephropathies, solidifying its role as a significant addition to nephrology therapeutics.
Filspari (sparsentan)
Endothelin antagonism: stepping into the spotlight.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Sparsentan: First Approval.
London, UK
2 hours ago
1 Received
- Sparsentan (FILSPARI™) is an oral medication that targets two specific receptors, being developed for conditions like IgA nephropathy and FSGS.
- In February 2023, it received accelerated approval by the FDA to lower protein levels in urine for adults with severe IgA nephropathy.
- The article reviews the key milestones in the development of sparsentan that led to its first approval for treating IgA nephropathy.
$100 - $150
Hourly Rate
IgA nephropathy: a review of existing and emerging therapies.
London, UK
2 hours ago
1 Received
- - IgA nephropathy (IgAN) is the most prevalent type of primary glomerulonephritis globally, with recent advances in understanding its causes and treatment options.
- - Individualizing treatment strategies and assessing patient risk for disease progression remains complex despite new therapies being available.
- - The review focuses on current management approaches for IgAN and emphasizes the numerous ongoing clinical trials that offer enrollment opportunities for patients.
$100 - $150
Hourly Rate
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study.
London, UK
2 hours ago
1 Received
- Sparsentan is a new type of medication being tested in the ongoing PROTECT trial for adults with IgA nephropathy (IgAN), with potential benefits in reducing inflammation and improving blood flow, without suppressing the immune system.
- The PROTECT trial is a large, international study comparing the effectiveness and safety of sparsentan against the active drug irbesartan in patients with significant proteinuria who have not found success with previous treatments.
- Results from 404 enrolled patients showed a mix of demographics and health statuses, which will help understand how sparsentan works across different populations and stages of chronic kidney disease (CKD).
$100 - $150
Hourly Rate
Sparsentan.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Interim analysis indicates sparsentan PROTECTs in IgAN.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice.
London, UK
2 hours ago
1 Received
- Alport syndrome (AS) is a genetic disorder that causes kidney disease and potentially hearing loss, typically treated with renin-angiotensin system inhibitors, but newer treatments are needed.
- Sparsentan, a dual receptor antagonist, demonstrated effectiveness in a mouse model for AS by reducing kidney and hearing-related issues, showing improvements in kidney function and lifespan compared to traditional treatments like losartan.
- The study suggests that sparsentan could be a promising therapy for patients with Alport syndrome, addressing both kidney damage and hearing loss, even when treatment starts after kidney issues have developed.
$100 - $150
Hourly Rate
Correction to: Sparsentan: First Approval.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis.
London, UK
2 hours ago
1 Received
- Sparsentan is a dual receptor antagonist being studied for treating focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), with a focus on understanding how disease characteristics and co-medications affect its pharmacokinetics (PK).
- A population PK analysis involved over 400 participants, including healthy volunteers and patients, using blood samples to determine how various factors influenced sparsentan's effectiveness and clearance.
- The final PK model indicated that co-administration of moderate to strong CYP3A4 inhibitors significantly increases sparsentan levels, suggesting potential dose adjustments for patients on these medications, while other analyzed factors may not require such changes.
$100 - $150
Hourly Rate
[Diagnosis and Treatment of IgA Nephropathy-2023].
London, UK
2 hours ago
1 Received
- Immunoglobulin A nephropathy (IgAN) is the most common form of glomerulonephritis, potentially leading to end-stage kidney disease in about a third of patients within 10 to 20 years, with its cause largely linked to immune system dysregulation involving IgA.
- Characteristic symptoms include nephritic urinary sediment, proteinuria, impaired kidney function, hypertension, and macrohematuria, but a definitive diagnosis requires a kidney biopsy and histological classification (MEST-C score) to predict outcomes.
- Treatment focuses on supportive measures such as blood pressure control and potential use of medications like SGLT2 inhibitors, with careful consideration needed for systemic immunosuppressive therapy and promising new drugs like
$100 - $150
Hourly Rate
Investigating the Impact of Selective Modulators on the Renin-Angiotensin-Aldosterone System: Unraveling Their Off-Target Perturbations of Transmembrane Ionic Currents.
London, UK
2 hours ago
1 Received
- The renin-angiotensin-aldosterone system (RAAS) is vital for regulating blood pressure, electrolyte balance, and cardiovascular health, and drugs affecting it may also influence ionic currents.
- Various compounds, like apocynin and esaxerenone, can modulate specific ionic currents while also interfering with the RAAS, showcasing their dual effects.
- Understanding how these substances interact with both the RAAS and ionic currents is essential for determining their mechanisms of action and potential health impacts.
$100 - $150
Hourly Rate
Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial.
London, UK
2 hours ago
1 Received
- Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease with significant treatment needs, and this study investigated how achieving complete remission (CR) of proteinuria relates to long-term kidney health.
- The analysis involved 108 patients from the DUET trial, finding that 43% achieved CR, particularly within the first year, and those with higher doses of the drug sparsentan or lower initial protein levels were more likely to achieve CR.
- Achieving CR was linked to a slower decline in kidney function, suggesting that sparsentan could provide sustained benefits in proteinuria management, indicating a positive response to treatment regardless of whether CR is maintained over time.
$100 - $150
Hourly Rate
Mass spectrometry-based gas phase intramolecular benzyl migration in sparsentan, a novel endothelin and angiotensin II receptor antagonist.
London, UK
2 hours ago
1 Received
- * Our study included tandem mass spectrometry to map out the relationships between precursor and fragment ions, allowing us to assign structures to major fragments resulting from the dissociation.
- * We proposed a benzyl migration mechanism based on computational analysis, offering insights into sparsentan's fragmentation pathways that could aid future research on similar molecules and their degradation products.
$100 - $150
Hourly Rate
Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice.
London, UK
2 hours ago
1 Received
- - IgA nephropathy (IgAN) is the most common type of glomerulonephritis and leads to kidney damage due to the buildup of IgA immune complexes, with 50% of patients experiencing significant kidney function loss in 10-20 years.
- - Persistent proteinuria is a major risk factor for disease progression, and current treatments focus on lowering protein levels and managing blood pressure.
- - Sparsentan, a newly FDA-approved medication, significantly reduces proteinuria compared to existing treatments and offers a non-immunosuppressive option for patients at high risk for IgAN progression, with a favorable safety profile.
$100 - $150
Hourly Rate
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
London, UK
2 hours ago
1 Received
- The PROTECT trial, a phase 3 study, evaluated the effectiveness of sparsentan, a dual receptor antagonist, in reducing proteinuria compared to irbesartan in patients with immunoglobulin A nephropathy over 110 weeks.* -
- A total of 406 patients were randomly assigned to either sparsentan or irbesartan, with the primary goal being the change in proteinuria at 36 weeks and secondary goals related to kidney function and safety over the trial duration.* -
- The findings from the trial, which included a significant reduction in proteinuria with sparsentan, provide important insights into potential treatment strategies for patients with kidney conditions.*
$100 - $150
Hourly Rate
Sparsentan - Another Arrow in the Quiver for Treatment of FSGS?
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
London, UK
2 hours ago
1 Received
- - A phase 3 trial investigated the long-term effects of sparsentan versus irbesartan in treating focal segmental glomerulosclerosis (FSGS) over 108 weeks, enrolling 371 patients aged 8 to 75.
- - At 36 weeks, sparsentan showed a significantly higher rate of partial remission of proteinuria (42%) compared to irbesartan (26%), and this positive response continued up to 108 weeks.
- - However, there were no significant differences in the estimated glomerular filtration rate (eGFR) slopes between the two groups at the final analysis, indicating that while proteinuria improved, kidney function as measured by eGFR remained similar with both treatments. *
$100 - $150
Hourly Rate
A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP).
London, UK
2 hours ago
1 Received
- Immunoglobulin A (IgA) vasculitis (IgAV), also known as Henoch-Schoenlein purpura, is the most common childhood vasculitis that usually resolves on its own, but can lead to significant kidney issues (IgAV-N) in some patients.
- Current treatments focus on established kidney involvement, but there's a push for early intervention to prevent inflammation before serious kidney damage occurs.
- Research is ongoing to identify new therapeutic targets and drugs aimed at preventing kidney problems in children with IgAV-N, as current options like corticosteroids have proven ineffective for this purpose.
$100 - $150
Hourly Rate
Status of current trials and potential future trials with sparsentan.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Treatment of IgA Nephropathy: A Rapidly Evolving Field.
London, UK
2 hours ago
1 Received
- * Effective treatment requires personalized care, with a focus on supportive measures, including sodium-glucose transporter 2 inhibitors and sparsentan, especially for patients with chronic kidney damage.
- * While glucocorticoids are useful for high-risk patients, their benefits diminish after stopping, and newer therapies like targeted-release budesonide and anti-B-cell strategies show promise for directly addressing the disease's underlying mechanisms.
$100 - $150
Hourly Rate